Anti-cancer Compounds

Summary

 

Technology Description

 

This technology describes using compounds to induce cell death in Bcl-2 high-expressing cancer cells refractory to chemotherapeutic drugs but with minimal effects on normal cells. Further, the anti-cancer effect of these compounds is also confirmed in mouse xenograft studies. These results indicate that our compounds are effective as Bcl-2 targeted therapeutics in cancers with high Bcl-2 expression.

 

Features & Benefits

 

  • Established mechanism of action and proven in vivo efficacy both on primary and metastatic tumor growth
  • Potential to derive additional novel analogs of our lead molecules

 

Applications

 

  • Cancer treatment

 

Background of Invention

 

The ratio of anti-cell death to pro-cell death proteins is an important factor controlling cell survival. Overexpression of anti-cell death Bcl-2 proteins in cancer facilitates initiation, progression, and also facilitates resistance of tumor cells to chemo and radiation therapies. Cancer cells commonly gain resistance to cancer therapies by overexpressing one or more of the pro-survival Bcl-2 proteins. Converting an anti-cell death protein into a pro-cell death protein is a novel approach for cancer treatment.

 

Status

 

Patent pending and available for licensing

 

Patent Information:
Tech ID:
OSU-16-62
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Siva Kolluri
Prasad Kopparapu
Keywords:
Cancer
metastatic tumor
small peptides
© 2017. All Rights Reserved. Powered by Inteum